The "C" class has been teaching the rest of the market a lesson this year, leading the way with oversized gains.» Read More
Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.
Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.
CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.
CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.
CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.
U.S. stock index futures briefly edged higher Wednesday following a better-than-expected durable goods orders report, but quickly erased gains to turn mixed again as investors remained cautious ahead of another EU summit later this week.
Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.
The "Squawk on the Street" team discusses the latest action in Facebook, Bristol-Myers and Eli Lilly.
Investors have made big bets on drugs like Pfizer's Lipitor for cholesterol, Glaxo's Advair for Asthma, and many more. CNBC's Seema Mody reports rare diseases might be the next hot investment.
Bristol-Myers' top selling blood thinner "Plavix" is going generic, reports CNBC's Seema Mody. Matt Cheslock, Virtu Financial, weighs in on how to trade the pharmaceuticals sector right now.
CNBC's Eamon Javers reports on Bristol-Meyers receiving a subpoena from the SEC. Also, Avon Group's Vice President Kerry Carr is resigning amid allegations of a bribery in China.
A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.
Mad Money's Jim Cramer, explains how big drug makers like, Pfizer and Bristol-Myers could pay off big time for investors.
Dr. Tony Coles, president & CEO of Onyx Pharmaceuticals, discusses his outlook on pharma in the new year. Biotech stocks were up 7% in 2011. "The emerging markets should be great for us," he adds.
Dendreon's revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drug's treatment of prostate cancer and an outlook on the healthcare sector, with Mitchell Gold, Dendreon president/CEO.
Barbara Ryan, analyst at Deutsche Bank, explains why she has a "buy" rating on Bristol Myers Squibb, Pfizer and Merk with a $43 price target. "Bristol Myers is clearly the growth name in the group," she adds.
Discussing a new drug that is extending patient's lives, with Michael Giordano, Bristo-Myers Squibb head of oncology.